The extracorporeal CO2 removal devices market is projected to reach US$ 182.88 million by 2031 from US$ 112.50 million in 2024. The market is estimated to register a CAGR of 7.3% during 2025-2031. Major factors driving the market growth include the rising prevalence of respiratory diseases, growing awareness of minimally invasive procedures, and an increasing geriatric population are propelling the adoption of extracorporeal CO2 removal devices. Further, rising demand in emerging economies will likely boost the market during the forecast period. However, high equipment cost and maintenance, lack of standardized clinical guidelines, stringent regulatory approvals are among the market deterrents.

One of the most persuasive factors driving the expansion of the extracorporeal CO? removal (ECCO?R) devices market is the global trend of an aging population, with people aged 60, 65, or older who suffer from chronic respiratory diseases and disproportionately experience acute respiratory failure. The World Health Organization (WHO) statistics indicate that the population aged 60 or over is expected to increase from an estimated 1.1 billion in 2023 to approximately 1.4 billion in 2030, and further to 2.1 billion by 2050, when they will constitute around 22% of the global population. Besides, older age has turned out to be one of the most notable factors in the occurrence of COPD and patient survival: in 2021, the global number of male cases and female cases among people aged 70-74 years were estimated to be 14 million and 15 million respectively, while the death rate and DALYs were highest in males aged 90-94 and females older than 95. It is suggested that older adults will likely be the primary users of the medical system, especially those segments related to respiratory care. In most cases, these people are not strong enough to endure the trauma caused by an invasive mechanical ventilation; therefore, ECCO?R is a good solution that can be simply a replacement or a supplement to it. The elderly population remains one of the primary structural factors driving the growth of the ECCO?R market, as these trends continue to evolve.

The comparative company analysis evaluates and categorizes the Extracorporeal CO2 Removal Devices market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global Extracorporeal CO2 Removal Devices market. The key market players are Medtronic Plc, Fresenius Medical Care AG & Co KGaA, Baxter International Inc, Eurosets SRL, Getinge AB, Medica S.p.A., Aferetica s.r.l., LivaNova Plc, ESTOR S.P.A., and Terumo Corp.

In terms of product, the extracorporeal CO2 removal devices market is bifurcated into extracorporeal CO2 devices and consumables. The extracorporeal CO2 devices segment held a larger market share in 2024, owing to growing usage of extracorporeal CO2 removal devices and prevalence of severe respiratory conditions worldwide that is leading the extracorporeal CO2 removal devices market.

Based on application, the extracorporeal CO2 removal devices market is categorized into chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others. The chronic obstructive pulmonary disease (COPD) segment accounted for the largest share of the extracorporeal CO2 removal devices market in 2024. The chronic obstructive pulmonary disease (COPD) segment accounted for the largest share of the extracorporeal CO2 removal devices market in 2024. The chronic obstructive pulmonary disease (COPD) segment is a significant and rapidly evolving field of application in the extracorporeal carbon dioxide removal (ECCO2R) market.

Based on end user, the extracorporeal CO2 removal devices market is categorized into hospitals and clinics, ambulatory surgical centers, and others. The hospitals and clinics segment held a larger share of the market in 2024. Hospitals and clinics are leading the way in the adoption of ECCO2R technology, primarily due to the acute need for the successful treatment of severe respiratory disorders.

Companies operating in the extracorporeal CO2 removal devices market adopt various organic and inorganic strategies. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses, enhance their geographic presence, and contribute to the overall market growth. Furthermore, acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few significant developments by key extracorporeal CO2 removal devices market players are listed below.

In July 2025, Medtronic plc announced a significant advancement in its mission to transform critical care - the VitalFlow Extracorporeal Membrane Oxygenation (ECMO) System has officially received CE (Conformit? Europ?enne) Mark approval in Europe. This milestone signals a significant leap forward in delivering seamless, life-saving support to the most fragile patients.

In October 2024, Fresenius Medical Care's heart & lung business unit, Xenios AG, introduces the all-new Xenios 2.0. This system enables healthcare professionals to take the next step in extracorporeal life support (ECLS). It can be used for the full range of ECLS treatments, from neonatal to adult patients, and is approved in accordance with the new Medical Device Regulation (MDR).

In September 2024, Medtronic plc announced the launch of a new ECMO system called VitalFlow, a configurable one-system ECMO solution built on simplicity and performance. The VitalFlow ECMO System bridges the gap between bedside care and intra-hospital transport, providing physicians and clinicians with a more seamless and intelligent ECMO experience.